$TRDA
Entrada Therapeutics, Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022003614 Filed on March 15, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.098M $15.20M $1.997M
YoY Change 205.36% 173.15%
% of Gross Profit
Research & Development $12.36M $35.93M $6.656M
YoY Change 85.73% 70.25%
% of Gross Profit
Depreciation & Amortization $364.0K $1.100M $98.00K
YoY Change 271.43% 266.67%
% of Gross Profit
Operating Expenses $18.46M $51.13M $8.653M
YoY Change 113.34% 91.72%
Operating Profit -$51.13M
YoY Change 91.72%
Interest Expense $13.00K -$31.00K -$20.00K
YoY Change -165.0% -121.53%
% of Operating Profit
Other Income/Expense, Net -$31.00K
YoY Change -121.53%
Pretax Income -$18.45M -$51.16M -$8.673M
YoY Change 112.69% 92.88%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$18.45M -$51.16M -$8.673M
YoY Change 112.69% 92.88%
Net Earnings / Revenue
Basic Earnings Per Share -$8.16
Diluted Earnings Per Share -$2.943M -$8.16 -$290.2K
COMMON SHARES
Basic Shares Outstanding 31.21M 6.268M
Diluted Shares Outstanding 6.268M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $291.1M $291.1M
YoY Change 645.46%
Cash & Equivalents $291.1M $291.1M $39.05M
Short-Term Investments
Other Short-Term Assets $7.636M $7.636M
YoY Change 744.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $298.7M $298.7M $39.95M
YoY Change 647.7% 647.7%
LONG-TERM ASSETS
Property, Plant & Equipment $6.261M $6.261M $3.037M
YoY Change 106.16% 106.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $872.0K $872.0K $541.0K
YoY Change 61.18% 61.18%
Total Long-Term Assets $7.133M $7.133M $3.578M
YoY Change 99.36% 99.36%
TOTAL ASSETS
Total Short-Term Assets $298.7M $298.7M $39.95M
Total Long-Term Assets $7.133M $7.133M $3.578M
Total Assets $305.8M $305.8M $43.53M
YoY Change 602.63% 602.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $706.0K $706.0K $1.602M
YoY Change -55.93% -55.93%
Accrued Expenses $6.013M $6.013M $1.757M
YoY Change 242.23% 242.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.719M $6.719M $3.359M
YoY Change 100.03% 100.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $396.0K $396.0K
YoY Change
Total Long-Term Liabilities $396.0K $396.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.719M $6.719M $3.359M
Total Long-Term Liabilities $396.0K $396.0K
Total Liabilities $7.115M $7.115M $3.359M
YoY Change 111.82% 111.82%
SHAREHOLDERS EQUITY
Retained Earnings -$93.67M -$42.51M
YoY Change 120.34%
Common Stock $3.000K $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $298.7M $298.7M -$41.49M
YoY Change
Total Liabilities & Shareholders Equity $305.8M $305.8M $43.53M
YoY Change 602.63% 602.63%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$18.45M -$51.16M -$8.673M
YoY Change 112.69% 92.88%
Depreciation, Depletion And Amortization $364.0K $1.100M $98.00K
YoY Change 271.43% 266.67%
Cash From Operating Activities -$20.54M -$50.86M -$6.624M
YoY Change 210.1% 98.91%
INVESTING ACTIVITIES
Capital Expenditures -$1.322M $4.580M -$1.451M
YoY Change -8.89% 97.58%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$1.322M -$4.580M -$1.451M
YoY Change -8.89% 97.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.8M 307.5M 149.0K
YoY Change 127923.49% 513.83%
NET CHANGE
Cash From Operating Activities -20.54M -50.86M -6.624M
Cash From Investing Activities -1.322M -4.580M -1.451M
Cash From Financing Activities 190.8M 307.5M 149.0K
Net Change In Cash 168.9M 252.0M -7.926M
YoY Change -2230.86% 1035.17%
FREE CASH FLOW
Cash From Operating Activities -$20.54M -$50.86M -$6.624M
Capital Expenditures -$1.322M $4.580M -$1.451M
Free Cash Flow -$19.22M -$55.44M -$5.173M
YoY Change 271.53% 98.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.16
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.00
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6267776
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1105260
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6267776
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1105260
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.16
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.00
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001689375
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2021Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1382
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7677000
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
85299885
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-40969
CY2021 dei Entity Registrant Name
EntityRegistrantName
ENTRADA THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3983399
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
6 Tide Street
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
CY2021 dei City Area Code
CityAreaCode
857
CY2021 dei Local Phone Number
LocalPhoneNumber
520-9158
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
TRDA
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q4 dei Entity Public Float
EntityPublicFloat
474900000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31251484
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
291064000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39045000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7636000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
904000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
298700000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
39949000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6261000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3037000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
872000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
541000
CY2021Q4 us-gaap Assets
Assets
305833000
CY2020Q4 us-gaap Assets
Assets
43527000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
331000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
706000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-41490000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305833000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43527000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35926000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21102000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15201000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5565000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1602000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6013000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1757000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6719000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3359000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
396000
CY2021Q4 us-gaap Liabilities
Liabilities
7115000
CY2020Q4 us-gaap Liabilities
Liabilities
3359000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
81658000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113259306
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31336092
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1283545
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31224336
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1244139
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
392384000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1021000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93669000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42511000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
298718000
CY2021 us-gaap Operating Expenses
OperatingExpenses
51127000
CY2020 us-gaap Operating Expenses
OperatingExpenses
26667000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-51127000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-26667000
CY2021 trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
-31000
CY2020 trda Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
144000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
144000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-51158000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-26523000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.16
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.00
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6267776
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1105260
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
37269149
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
31816000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
541000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
213000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-715000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
631000
CY2020 us-gaap Profit Loss
ProfitLoss
-26523000
CY2021 us-gaap Depreciation
Depreciation
1117000
CY2020 us-gaap Depreciation
Depreciation
326000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22201000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39045000
CY2020 trda Proceeds From Early Exercise Of Stock Options
ProceedsFromEarlyExerciseOfStockOptions
34000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-74000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-20000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2526000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
325000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6733000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
311000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16844000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-15518000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
214000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2020 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
11000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
325000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-26523000
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
85299885
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
81658000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-41490000
CY2021 trda Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities
TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
138821984
CY2021 trda Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities
TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
197489000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
197489000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
18034000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
190691000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
410000
CY2021 trda Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
250000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2526000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-51158000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
298718000
CY2021 us-gaap Profit Loss
ProfitLoss
-51158000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3962000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
578000
CY2021 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
396000
CY2020 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-75000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50862000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25570000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4580000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2318000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4580000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2318000
CY2021 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
115831000
CY2020 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
49842000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
190691000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
410000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
307461000
CY2021 trda Proceeds From Early Exercise Of Stock Options
ProceedsFromEarlyExerciseOfStockOptions
529000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50089000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
252019000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
291064000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39045000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
155000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
320000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
197489000
CY2020 trda Vesting Of Restricted Stock Subject To Repurchase
VestingOfRestrictedStockSubjectToRepurchase
1000
CY2021 trda Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
250000
CY2020 trda Vesting Of Options Early Exercised Subject To Repurchase
VestingOfOptionsEarlyExercisedSubjectToRepurchase
11000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-51200000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-26500000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93700000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
291100000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to accrual and prepayment of research and development expenses and stock-based compensation. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</p>
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p>
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3414000
CY2020Q4 us-gaap Litigation Reserve
LitigationReserve
0
CY2021Q4 us-gaap Litigation Reserve
LitigationReserve
0
CY2021 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations (CROs), business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</p>
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
85299885
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1416000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
377000
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
85299885
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
81658000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
88377000
CY2020Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
11788435
CY2021 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
291100000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
39000000.0
CY2021Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
19185183
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6261000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3037000
CY2021 us-gaap Depreciation
Depreciation
1100000
CY2020 us-gaap Depreciation
Depreciation
300000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4077000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1482000
CY2021Q4 trda Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1032000
CY2020Q4 trda Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
125000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
419000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
35000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
485000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
115000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6013000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1757000
CY2021 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
CY2020 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2021 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2021Q4 trda Number Of Directors Entitled To Be Elected
NumberOfDirectorsEntitledToBeElected
3
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 trda Number Of Votes Per Share Of Common Stock
NumberOfVotesPerShareOfCommonStock
1
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113259306
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 trda Number Of Votes Per Share Of Common Stock
NumberOfVotesPerShareOfCommonStock
1
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6583887
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13785534
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2500000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2526000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
325000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
111756
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
27869
CY2021Q4 trda Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount
300000
CY2020Q4 trda Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount
100000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13240000
CY2021Q4 trda Operating Loss Carryforwards Subject To Expiration
OperatingLossCarryforwardsSubjectToExpiration
3200000
CY2021Q4 trda Operating Loss Carryforwards Limitation On Use Amount
OperatingLossCarryforwardsLimitationOnUseAmount
89900000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
6000000.0
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
1900000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.061
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.039
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.040
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.307
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.310
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25124000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11214000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3237000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1236000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
761000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
432000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
313000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
430000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
80000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
137000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
76000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29689000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13351000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
261000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
111000
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
485000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
746000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
111000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28943000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8526000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8384000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16910000
CY2020 trda Expenses Relating To Milestone Obligation
ExpensesRelatingToMilestoneObligation
0
CY2021 trda Expenses Relating To Milestone Obligation
ExpensesRelatingToMilestoneObligation
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-51158000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-26523000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6267776
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1105260
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.16
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.00
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3573626
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13453097

Files In Submission

Name View Source Status
0001558370-22-003614-index-headers.html Edgar Link pending
0001558370-22-003614-index.html Edgar Link pending
0001558370-22-003614.txt Edgar Link pending
0001558370-22-003614-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trda-20211231.xsd Edgar Link pending
trda-20211231x10k.htm Edgar Link pending
trda-20211231x10k006.jpg Edgar Link pending
trda-20211231x10k007.jpg Edgar Link pending
trda-20211231x10k008.jpg Edgar Link pending
trda-20211231x10k009.jpg Edgar Link pending
trda-20211231x10k010.jpg Edgar Link pending
trda-20211231x10k011.jpg Edgar Link pending
trda-20211231x10k012.jpg Edgar Link pending
trda-20211231x10k013.jpg Edgar Link pending
trda-20211231x10k014.jpg Edgar Link pending
trda-20211231x10k015.jpg Edgar Link pending
trda-20211231x10k016.jpg Edgar Link pending
trda-20211231x10k017.jpg Edgar Link pending
trda-20211231x10k018.jpg Edgar Link pending
trda-20211231x10k019.jpg Edgar Link pending
trda-20211231x10k020.jpg Edgar Link pending
trda-20211231x10k021.jpg Edgar Link pending
trda-20211231x10k022.jpg Edgar Link pending
trda-20211231x10k023.jpg Edgar Link pending
trda-20211231x10k024.jpg Edgar Link pending
trda-20211231x10k025.jpg Edgar Link pending
trda-20211231x10k026.jpg Edgar Link pending
trda-20211231x10k027.jpg Edgar Link pending
trda-20211231x10k028.jpg Edgar Link pending
trda-20211231x10k029.jpg Edgar Link pending
trda-20211231x10k030.jpg Edgar Link pending
trda-20211231x10k031.jpg Edgar Link pending
trda-20211231x10k032.jpg Edgar Link pending
trda-20211231x10k033.jpg Edgar Link pending
trda-20211231x10k034.jpg Edgar Link pending
trda-20211231x10k035.jpg Edgar Link pending
trda-20211231x10k036.jpg Edgar Link pending
trda-20211231x10k037.jpg Edgar Link pending
trda-20211231x10k038.jpg Edgar Link pending
trda-20211231x10k039.jpg Edgar Link pending
trda-20211231x10k040.jpg Edgar Link pending
trda-20211231x10k041.jpg Edgar Link pending
trda-20211231x10k042.jpg Edgar Link pending
trda-20211231x10k043.jpg Edgar Link pending
trda-20211231x10k044.jpg Edgar Link pending
trda-20211231x10k045.jpg Edgar Link pending
trda-20211231x10k_htm.xml Edgar Link completed
trda-20211231xex21d1.htm Edgar Link pending
trda-20211231xex23d1.htm Edgar Link pending
trda-20211231xex31d1.htm Edgar Link pending
trda-20211231xex31d2.htm Edgar Link pending
trda-20211231xex32d1.htm Edgar Link pending
trda-20211231xex4d3.htm Edgar Link pending
trda-20211231_cal.xml Edgar Link unprocessable
trda-20211231_def.xml Edgar Link unprocessable
trda-20211231_lab.xml Edgar Link unprocessable
trda-20211231_pre.xml Edgar Link unprocessable